This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merck Won't Yield on Yield

Just about any time a Merck (MRK) executive appears before a microphone, presides over a Webcast or attends a financial or medical conference, he or she is asked how safe the dividend is.

The question has been posed ever since Sept. 30, 2004, when Merck pulled the arthritis drug Vioxx from the market, and every time the New Jersey-based drugmaker says its payment isn't in danger.

However, investors can expect this Q&A to continue, perhaps for years, as long as there's uncertainty about potential liabilities of Vioxx.

Wall Street estimates of those liabilities run as high as $55 billion. But the dividend is only part of the financial dilemma for Merck, which is facing several years of declining earnings per share and sales growth.

Merck doesn't have enough new drugs with large-sales potential to offset the lost revenue from big-sellers going off patent, but don't expect any drastic dividend action soon. Merck still has a healthy credit rating.

The company's balance sheet also has been bolstered, thanks to a law signed by President Bush last year that enables companies to repatriate earnings from foreign subsidiaries at sharply reduced tax rates. Merck is repatriating $15 billion.

Still, there's that nagging question. Merck's yield of 5.1% -- second-highest among its peers -- has been attractive to investors willing to wait out the bad times. They might be waiting a while, according to Albert Rauch of A.G. Edwards.

"Our concern is that it will be a long time for the turnaround -- 2008, or even 2009 or 2010," he says.

Stock Support

Cutting the dividend would scare investors because they might interpret the move to mean that Merck fears big Vioxx litigation losses, Rauch says. Merck hasn't established a reserve for potential liabilities, but it has set aside $675 million just for legal expenses.

Big Pharma's Dividends
Company Dividend (Per Share Annual Rate) Share Price Dec. 1 Yield
Bristol-Myers Squibb $1.12 $21.63 5.20%
Merck $1.52 $29.68 5.10%
Pfizer $0.76 $21.38 3.50%
Eli Lilly $1.52 $51.50 3.00%
Abbott $1.10 $37.63 2.90%
Wyeth $1 $41.20 2.40%
Schering-Plough $0.22 $19.05 1.20%

Right now, the dividend is propping up the stock. Rauch says Wall Street is valuing Merck for its ability to maintain the payout rather than its earnings per share performance. Clearly, a dividend cut would send Merck's shares lower. If the price fell too low, Merck could even become a takeover target, says Rauch, who doesn't own shares and whose firm doesn't have an investment banking relationship with the company.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs